Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
Sehested T, Bjerre J, Ku S, Chang A, Jahansouz A, Owens D, Hlatky M, Goldhaber-Fiebert J. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. JAMA Cardiology 2019, 4: 128-135. PMID: 30649147, PMCID: PMC6439626, DOI: 10.1001/jamacardio.2018.4566.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness ratioIncremental cost-effectiveness ratioRecurrent cardiovascular eventsHealth-related quality of lifeStandard of careCanakinumab Anti-inflammatory Thrombosis Outcomes StudyHs-CRP levelsLung cancer incidenceHealth-related qualityMyocardial infarctionCardiovascular eventsRate of recurrent MIHealth care sector perspectiveReduced all-cause mortalityQuality of lifeAll-cause mortalityCost-effectiveUS health care sector perspectiveHs-CRPCancer incidenceRisk of recurrent cardiovascular eventsMain OutcomesHigh-sensitivity C-reactive proteinSubstantial price reductions